Skip to content
AnalystLens

HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 30, 2024)

Reports
Earnings & Results·Leadership Changes·Regulation FD+2
Filing Date
Filed January 30, 2024
Period End
January 24, 2024
Security
HCA
In the record · 2016–202610-K1110-Q328-K144

HCA filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 144 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’18Mar ’18
  2. Material agreement8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Jun ’26Jun ’26

01—Abstract

Summary

Summary of the 8-K filed January 30, 2024. Cited figures are marked; the original filing is the authoritative source.

HCA Healthcare reported fourth-quarter 2023 revenues of $17.303 billiona, up from $15.497 billion a year earlier, with net income attributable to HCA of $1.607 billion, or $5.93 per diluted share, versus $7.28 in 4Q 2022.

The comparison is distorted by a $1.326 billionb gain on facility sales in 4Q 2022 (worth $2.64 per share); excluding gains and losses on facility sales and debt retirement, 4Q 2023 EPS was $5.90 versus $4.64 a year earlier, a sizable improvement. Adjusted EBITDA rose about 14% to $3.618 billion, with the margin widening to 20.9% from 20.5%. Volume and pricing both contributed: same facility admissions rose 3.1% and revenue per equivalent admission rose 6.9%, reflecting strong demand and improved cost trends.

For full-year 2023, revenues were $64.968 billionc, Adjusted EBITDA was $12.726 billion, and diluted EPS was $18.97, compared with $19.15 in 2022 (which included large facility-sale gains). The company guided to 2024 revenues of $67.75 to $70.25 billion, Adjusted EBITDA of $12.85 to $13.55 billion, and diluted EPS of $19.70 to $21.20. Capital expenditures are expected at $5.1 to $5.3 billion.

The guidance midpoint implies modest EBITDA growth but a higher capital spending burden. Capital allocation remains shareholder-friendly: the Board authorized an additional $6 billiond buyback, on top of $775 million remaining at year-end, and declared a $0.66 quarterly dividend. Balance sheet leverage is significant, with total debt of $39.593 billion against cash of $935 million, though the company had $6.107 billion of credit facility availability.

Leadership is also changing. CFO Bill Rutherford retires effective May 1, 2024, after ten years as CFO and 34 years with the company. He will be succeeded by Michael A.

Marks, a 34-year HCA veteran who is currently Senior Vice President, Finance. Marks's compensation includes a $900,000 base salary and a $2 million target long-term equity award, split between stock appreciation rights and performance share units tied to a three-year cumulative EPS goal. The transition is orderly, with an internal successor who has worked closely with the outgoing CFO, which should reassure investors about continuity.

02—Key points

Key Highlights

  1. 4Q 2023 revenues rose about 11.6% year over year to $17.303 billion, driven by same facility admissions growth of 3.1% and revenue per equivalent admission growth of 6.9%.
  2. 4Q 2023 Adjusted EBITDA increased about 14% to $3.618 billion, with the margin expanding to 20.9% from 20.5%.
  3. Diluted EPS of $5.93 is down from $7.28 only because 4Q 2022 included a $2.64 per-share facility-sale gain; excluding these items, EPS rose to $5.90 from $4.64.
  4. 2024 guidance calls for revenues of $67.75–$70.25 billion, Adjusted EBITDA of $12.85–$13.55 billion, and diluted EPS of $19.70–$21.20.
  5. Board authorized an additional $6 billion share repurchase program and declared a $0.66 quarterly dividend, payable March 29, 2024.
  6. CFO Bill Rutherford retires effective May 1, 2024; internal successor Michael A. Marks, a 34-year HCA veteran, will take over.
  7. Total debt of $39.593 billion remains a significant leverage consideration, though the company had $6.107 billion in credit facility availability.

03—Questions

Frequently Asked Questions

  1. Why did reported EPS decline year over year if operating results improved?

    The 4Q 2022 figure of $7.28 included a $1.326 billion gain on facility sales ($2.64 per diluted share). Excluding gains and losses on facility sales and debt retirement, EPS rose from $4.64 in 4Q 2022 to $5.90 in 4Q 2023, so underlying performance improved.

  2. What drove the growth in 4Q 2023 revenue?

    Growth came from both volume and price. Same facility admissions rose 3.1%, same facility equivalent admissions rose 3.9%, and same facility revenue per equivalent admission rose 6.9%. Same facility ER visits rose 2.1%.

  3. What does the 2024 guidance imply for investors?

    Guidance midpoints are about $69 billion in revenue, $13.2 billion in Adjusted EBITDA, and $20.45 in diluted EPS. Capital expenditures of $5.1–$5.3 billion are expected, which is a heavy investment load relative to EBITDA. The guidance excludes gains and losses on facility sales, debt retirement, legal claims, and asset impairments.

  4. How is the company returning capital to shareholders?

    HCA authorized a new $6 billion buyback on top of $775 million remaining at year-end 2023, and declared a $0.66 quarterly dividend. In 2023 the company repurchased $3.811 billion of stock and paid $661 million in dividends. Repurchases are discretionary and the program has no time limit.

  5. Is the CFO transition a concern for investors?

    The transition appears orderly. Rutherford is retiring after 34 years and ten years as CFO, and Michael Marks has been with HCA since 1996, most recently as Senior Vice President, Finance, and has worked closely with Rutherford and the senior team. His $900,000 base salary and $2 million target equity award are tied to stock appreciation rights and EPS-based performance units, aligning his incentives with shareholders.

04—Continue

← View all 8-K filings